It is my pleasure to welcome you to the Tufts Center for the Study of Drug Development (Tufts CSDD) website. We invite you to browse and learn more about our research activities, publications, professional development courses, roundtable forums, and information services.
We’ve added several new features to make your visit even more enjoyable and productive. We’ve streamlined the design of the site and improved navigation and overall accessibility. Many of our website sections have been archived and enhanced making it easier for you to conduct targeted searches of our publications and resources. Our new Media Center enables faster and easier communication with members of the Tufts CSDD team.
For nearly 50 years, we have provided scholarly assessments of the time, cost, and risk of drug development innovation as well as the trends, factors, and practices impacting drug development performance. Today, Tufts CSDD at the Tufts University School of Medicine is the only multidisciplinary academic research center dedicated to optimizing drug development performance, efficiency, quality and economics through robust, empirical assessments and evidence-based analyses.
Because of our reputation for scholarly and objective insights drawn from hard evidence, we are frequently asked to provide public testimony at U.S. Congressional and state-level hearings; interact with international regulatory agencies and health authorities; prepare executive reports and white papers; and speak at conferences, webinars, committee meetings, and public forums.
Each year Tufts CSDD conducts independent research studies funded by foundations, government agencies, professional associations, and the private sector. Tufts CSDD also conducts several working group studies annually involving the input and participation of organizations active throughout the clinical research enterprise. And, in recent years Tufts CSDD has helped form and facilitate several pre-competitive consortia.
The challenges of developing pharmaceutical innovations are intensifying as R&D complexity, customization, and fragmentation increase. All stakeholders involved — pharmaceutical and biotechnology companies, regulators, policymakers, public and private investigative sites and site networks, technology companies, investors, and contract service providers — need data and actionable insights to improve drug development performance, efficiency, and economics. The work of the Tufts Center could not be more important or relevant.
Please contact us via email at @email or phone at 617-636-2170 for more information.
We hope you enjoy your visit to our updated website.
Kenneth Getz, MBA
Executive Director and Research Professor
Tufts CSDD